ENTITY
Kyowa Kirin Co Ltd

Kyowa Kirin Co Ltd (4151 JP)

93
Analysis
Health Care • Japan
Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.
more
•24 Sep 2021 21:49

Global Energy Sector Improving -- Buying Reliance Industries Ltd, Several Others

Crude oil prices display bullish short-term reversals, resulting in bullish price and RS reversals for global Energy stocks -- add exposure.

Logo
635 Views
Share
•10 Jun 2021 09:11

Global Equity Strategy: Opportunities In Real Estate and Health Care

The weight of the evidence continues to support our mixed, but overall constructive outlook. We outline the basis for our outlook and also...

Logo
365 Views
Share
bullish•Nippon Shinyaku
•28 May 2026 08:30

Nippon Shinyaku (4516 JP): FY27 Guidance Signals Recovery, Speed Bumps Remain

​Nippon Shinyaku's FY26 revenue grew 7% to ¥170B, driven by ethical drugs and higher licensing fees. FY27 revenue expected to reach ¥200B with...

Logo
121 Views
Share
•22 Dec 2018 13:51

Japan Pharma - Domestic Market and Long Listed Drug Exposure

The Japanese government recently announced its decision to initiate an ad-hoc price reduction of ~4.35%, to be levied in October 2019, this will...

bullish•Shionogi & Co
•15 May 2026 08:30

Shionogi & Co (4507 JP): FY26 Result Falls Short of Expectation; Mixed Guidance for FY27

​Shionogi announces FY26 results, with revenue meeting but operating profit missing guidance due to higher expenses. The company expects 32%...

Logo
96 Views
Share
x